WCLC 2022 | Mechanism of action of the novel KRASG12C inhibitor GDC-6036
Adrian Sacher, MD, Princess Margaret Cancer Centre, Toronto, Canada, explains the mechanism of action of the novel KRASG12C KRAS inhibitor GDC-6036, which binds to and locks KRAS in an inactive state to prevent further KRAS downstream signaling. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
Transcript (edited for clarity)
GDC-6036 is a novel KRASG12C inhibitor. It works by binding to an essentially locking KRASG12C into an inactive state. As a result, it prevents further downstream KRS signaling. What’s unique about GDC6036 is that it is more selective and potent than previous KRASG12C, hence all the promise and interest in it.
GDC-6036 is a novel KRASG12C inhibitor. It works by binding to an essentially locking KRASG12C into an inactive state. As a result, it prevents further downstream KRS signaling. What’s unique about GDC6036 is that it is more selective and potent than previous KRASG12C, hence all the promise and interest in it.
Read more...
